A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative treatment for multiple myeloma (MM); however, due to high-treatment related mortality (TRM) its role is not well defined. METHODS: Patients with newly diagnosed, relapsed, or primary refractory myelom...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Bashir, Qaiser, Khan, Hassan, Thall, Peter F, Liu, Ping, Shah, Nina, Kebriaei, Partow, Parmar, Simrit, Oran, Betul, Ciurea, Stefan, Nieto, Yago, Jones, Roy, Hosing, Chitra M, Popat, Uday R, Dinh, Yvonne T, Rondon, Gabriela, Orlowski, Robert Z., Shah, Jatin J, De Lima, Marcos, Shpall, Elizabeth, Champlin, Richard, Giralt, Sergio, Qazilbash, Muzaffar
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4157818/
https://ncbi.nlm.nih.gov/pubmed/23872222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.07.008
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk